Case Study: an early-stage US-based pharmaceutical company achieves ~80% faster gene target identification and validation with Elucidata

early-stage US-based pharmaceutical company accelerates gene target ID and validation by ~80% with Elucidata

An early-stage US-based pharmaceutical company was studying gene perturbation to develop a novel treatment but faced significant delays in target identification and validation. They partnered with Elucidata to leverage its data curation infrastructure and processing pipelines to accelerate this process.

Elucidata completed the custom curation of over 50 datasets in just two months. This enabled the identification of two high-potential targets that regulate cell fate reprogramming. The solution dramatically increased the overall speed of analysis, allowing the customer to identify and validate these targets in 5-6 months instead of the typical timeframe of more than a couple of years, achieving an approximately 80% acceleration.